tiprankstipranks
Trending News
More News >
Xspray Pharma AB (SE:XSPRAY)
:XSPRAY

Xspray Pharma AB (XSPRAY) AI Stock Analysis

Compare
1 Followers

Top Page

SE

Xspray Pharma AB

(Berlin:XSPRAY)

Rating:47Neutral
Price Target:
Xspray Pharma AB's stock score reflects significant financial challenges, particularly the lack of revenue and increasing debt levels, which weigh heavily on the overall assessment. While technical indicators show some positive momentum, they are not strong enough to offset the financial concerns. The stock's valuation, characterized by a negative P/E ratio, underscores the company's unprofitability. To improve the stock's attractiveness, achieving revenue generation and financial sustainability will be critical.

Xspray Pharma AB (XSPRAY) vs. iShares MSCI Sweden ETF (EWD)

Xspray Pharma AB Business Overview & Revenue Model

Company DescriptionXspray Pharma AB (XSPRAY) is a Swedish pharmaceutical company that specializes in developing improved versions of already approved and marketed drugs. The company focuses on creating novel formulations using its proprietary HyNap technology platform, which enhances the solubility and absorption of drugs. Xspray Pharma primarily targets the oncology sector, aiming to provide competitive alternatives to existing cancer treatments with better efficacy and safety profiles.
How the Company Makes MoneyXspray Pharma makes money by developing and commercializing improved versions of existing cancer drugs. The company's revenue model is based on licensing agreements and collaborations with larger pharmaceutical companies that have the resources and distribution networks to market the drugs. By using its HyNap technology, Xspray creates formulations that offer competitive advantages over original drugs, such as enhanced bioavailability and reduced side effects, making them attractive for licensing. Xspray typically earns upfront payments, milestone payments, and royalties from these partnerships. Additionally, the company may also generate revenue through direct sales if it chooses to commercialize certain products independently.

Xspray Pharma AB Financial Statement Overview

Summary
Xspray Pharma AB faces significant financial challenges typical of early-stage biotechnology firms, such as lack of revenue generation and profitability. The strong equity position and liquidity provide some stability, but the reliance on external funding and increasing debt levels pose future risks. A focus on achieving operational efficiency and revenue generation is critical for improving financial health.
Income Statement
20
Very Negative
Xspray Pharma AB has consistently reported zero revenue over the years, indicating a lack of commercial operations or product sales. The company has been experiencing increasing losses, with net income significantly negative, which reflects ongoing financial challenges in achieving profitability. The EBIT and EBITDA margins are negative, further emphasizing the lack of operational efficiency and profitability.
Balance Sheet
45
Neutral
The balance sheet shows a strong equity position with a high equity ratio, indicating a solid capital base. However, the company has been increasing its debt levels, which is reflected in a rising debt-to-equity ratio. Despite the challenges, a substantial portion of the assets consists of cash and short-term investments, providing some liquidity cushion.
Cash Flow
30
Negative
Xspray Pharma AB has been generating negative operating and free cash flows, indicating cash burn from operations and investments. The company relies heavily on financing activities for cash inflows, which could be a concern if external funding becomes less accessible. No positive growth in free cash flow has been observed, signaling potential sustainability issues.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue930.00K0.000.000.000.000.00
Gross Profit930.00K0.00-9.19M-9.53M-8.87M-1.41M
EBITDA-247.26M-277.76M-169.81M-122.13M-87.82M-50.99M
Net Income-260.07M-285.52M-179.67M-130.27M-96.70M-52.30M
Balance Sheet
Total Assets737.71M796.34M765.26M585.43M622.90M605.30M
Cash, Cash Equivalents and Short-Term Investments125.72M208.24M166.30M120.17M271.88M325.60M
Total Debt126.96M128.22M36.81M2.13M3.23M4.86M
Total Liabilities157.25M173.25M71.85M29.41M31.15M22.72M
Stockholders Equity580.46M623.10M693.41M556.02M591.75M582.59M
Cash Flow
Free Cash Flow-285.08M-264.51M-257.38M-238.47M-147.57M-145.00M
Operating Cash Flow-233.39M-222.37M-203.28M-110.18M-51.61M-47.79M
Investing Cash Flow-51.69M-42.14M-65.88M-135.34M-105.82M-96.83M
Financing Cash Flow306.54M306.11M315.59M93.81M103.71M260.35M

Xspray Pharma AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price45.90
Price Trends
50DMA
35.76
Positive
100DMA
33.26
Positive
200DMA
38.78
Positive
Market Momentum
MACD
3.95
Negative
RSI
73.00
Negative
STOCH
78.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XSPRAY, the sentiment is Positive. The current price of 45.9 is above the 20-day moving average (MA) of 39.78, above the 50-day MA of 35.76, and above the 200-day MA of 38.78, indicating a bullish trend. The MACD of 3.95 indicates Negative momentum. The RSI at 73.00 is Negative, neither overbought nor oversold. The STOCH value of 78.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XSPRAY.

Xspray Pharma AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
kr1.38B5.27152.78%1533.99%
64
Neutral
¥342.56B10.47-2.86%2.57%11.81%-7.17%
48
Neutral
kr1.06B-48.22%67.70%
47
Neutral
kr1.75B-42.24%-19.44%
47
Neutral
kr373.24M-47.73%45.52%93.35%
37
Underperform
kr334.03M-194.31%1643.36%50.36%
31
Underperform
kr334.63M-167.55%46.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:XSPRAY
Xspray Pharma AB
48.30
-30.26
-38.52%
SE:CANTA
Cantargia AB
1.33
-2.82
-67.89%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
3.70
-9.38
-71.70%
SE:SANION
Saniona AB
10.20
6.69
190.60%
SE:XBRANE
Xbrane Biopharma AB
0.25
0.03
12.73%
SE:SYNACT
SynAct Pharma AB
21.20
12.28
137.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 01, 2025